Treatment of SARS-CoV-2 (COVID-19) cases by the oral administration of montelukast tablets

Ameneh Norouzi

DOI: 10.21931/RB/2020.05.04.5

Abstract: According to the hypothesis, montelukast may have therapeutic action against severe acute respiratory syndrome (SARS) occurred by coronavirus 2 (CoV-19). The research was aimed to evaluate the therapeutic effects of montelukast tablet on coronavirus infectious disease (COVID-19) patients. A total of 20 COVID-19 confirmed patients were included in this study. The presence of COVID-19 infections in all patients was confirmed using real-time polymerase chain reaction (RT-PCR) and computerized tomography (CT) scan. Confirmed cases were treated with oral administration of montelukast (10 mg) tablet for 10 days. The study population was included 18 to 82 years old patients (10 males and 10 females). The mean age of studied men and women individuals were 44.7±17 and 41±17.45 years, respectively. Frequency of respiratory distress, cough, abdominal cramps/diarrhea, fever, and odor disorder clinical signs amongst the examined patients were 85%, 90%, 20%, 70%, and 65%, respectively. Our findings revealed that all patients who received 10 days of oral administration of montelukast tablets (10 mg) were recovered from the COVID-19 disease. Additionally, all of the clinical signs of COVID-19 patients, including respiratory distress, cough, and odor disorder, were gradually disappeared. Our findings revealed that widespread oral administration of montelukast tablets (10 mg) is a potential treatment for COVID-19 disease. However, several double-blind and multifactorial clinical trials should perform to determine the other clinical aspects of the treatment of COVID-19 patients by oral administration of montelukast.

Key words: SARS-COVID-19, Treatment, Montelukast.

Introduction

Infectious diseases remain a threatening issue for human health despite the high development of medical sciences. Severe Acute Respiratory Syndrome (SARS)-Coronavirus Diseases-19 (CoVID-19) which also known as SARS-CoV-2, is the essential threatening disease in 2019 and 2020 years all around the world. Coronaviruses (CoVs) belong to the family of Coronaviridae, the order Nidovirales, and the genus Coronavirus, with a positive sense, single-stranded RNA genome. Human coronaviruses (HCoVs), are documented as respiratory pathogens related to respiratory and intestinal infections with various severities from the usual cold to pneumonia and bronchiolitis to death. COVID-19, as a deadly disease is occurred owing to the activity of SARS-CoV-2, accounted as a global public health concern.

Montelukast, the present research was done to assess the effects of oral administration of montelukast as a therapeutic agent for the treatment of SARS-CoV-2 patients. According to the hypothesis, montelukast may have therapeutic action against severe acute respiratory syndrome (SARS) occurred by coronavirus 2 (CoV-19). The research was aimed to evaluate the therapeutic effects of montelukast tablet on coronavirus infectious disease (COVID-19) patients. A total of 20 COVID-19 confirmed patients were included in this study. The presence of COVID-19 infections in all patients was confirmed using real-time polymerase chain reaction (RT-PCR) and computerized tomography (CT) scan. Confirmed cases were treated with oral administration of montelukast (10 mg) tablet for 10 days. The study population was included 18 to 82 years old patients (10 males and 10 females). The mean age of studied men and women individuals were 44.7±17 and 41±17.45 years, respectively. Frequency of respiratory distress, cough, abdominal cramps/diarrhea, fever, and odor disorder clinical signs amongst the examined patients were 85%, 90%, 20%, 70%, and 65%, respectively. Our findings revealed that all patients who received 10 days of oral administration of montelukast tablets (10 mg) were recovered from the COVID-19 disease. Additionally, all of the clinical signs of COVID-19 patients, including respiratory distress, cough, and odor disorder, were gradually disappeared. Our findings revealed that widespread oral administration of montelukast tablets (10 mg) is a potential treatment for COVID-19 disease. However, several double-blind and multifactorial clinical trials should perform to determine the other clinical aspects of the treatment of COVID-19 patients by oral administration of montelukast.

Materials and methods

Ethics and consents

The present survey was conducted on volunteer patients who suffered from SARS-COVID-19 disease. Informed consent was obtained from the patients or their parents involved in this survey. Additionally, all the identity and personal information of the patients participating in this study remained secret. Ethical principles of patient care and sampling were also observed. Serious efforts were made to reduce patients’ pain and anxiety during the research process.

Study population

A total of 20 male and female ≥18 years old patients with clinical signs of COVID-19 disease were confirmed by the computerized tomography (CT)-scan and Real-Time Polymerase Chain Reaction (PCR) were included in this study.

Inclusion and exclusion criteria

All patients confirmed to be infected with the COVID-19 virus through the nucleic acid detection by the Real-Time PCR assay, and positive outcomes of chest CT-scan were included in the study. Additionally, clinical signs of the disease were considered. If both chest CT-scan and Real-Time PCR test showed negative findings of COVID-19 disease for any patients,
they were excluded from the study. Additionally, patients who died during the study and also those who used from other therapeutic options against SARS-COVID-19 were excluded from the research. Furthermore, patients with progressive and autoimmune diseases were excluded from the study.

COVID-19 virus detection and diseases confirmation in the study population

Patients were confirmed by Reverse transcription-Real-Time PCR (RT-Real-Time PCR) using throat swab specimens from the upper respiratory tract or clinically diagnosed based on lung imaging features, specially Chest CT scan ground glass pathognomonic features consistent with coronavirus pneumonia, depending on the physician’s orders.

The presence of the COVID-19 virus was examined using the RT-Real-Time PCR method. For this purpose, the method described previously was used. Throat swab samples were used for RNA extraction. Lesser than 37 cycle threshold values (Ct-value) were considered as a positive, while those of higher than 40 were recognized as negative. Additionally, a chest CT scan was performed, and its results were analyzed according to lung involvements, density (ground-glass and consolidations), and central to peripheral distribution.

Treatment protocol

Confirmed patients with CT-scan and RT-Real-Time PCR were subjected to oral administration of montelukast tablets (10 mg, Dr. Abidi Co, Tehran, Iran) for about 10 days. Patients were used two montelukast tablets on the first day of the experiment and then only one table from days 2 to 10 of the experiment. Routine cares of COVID-19 were addressed for all patients.

Statistical analysis

All data collected from the study were transferred to Microsoft Excel software (Microsoft Corp., Redmond, WA, USA). Statistical analyses were performed using SPSS 21.0 (Statistical Package for the Social Sciences) software (SPSS Inc., Chicago, IL, USA). Variables were defined as frequencies and percentages. A comparison of the differences was conducted using the Chi-square test. P-value<0.05 was considered statistically significant.

Results

COVID-19 identification

The present survey was performed to assess the therapeutic effects of oral administration of montelukast tablet (10 mg) in patients suffered from COVID-19 disease. Figure 1 represents the pattern of lung CT-scan in some of the examined COVID-19 patients. As shown, multi-lobar and bilateral ground-glass opacities are seen in both lungs, mostly in mid to lower lungs, although all lobes are affected, with a peripheral subpleural distribution. Additionally, the presence of the COVID-19 virus was identified by the Real-Time PCR method in all examined patients.

Study population

Table 1 represents the characters of the study population of COVID-19 patients. The study population consisted of 18 to 82 years old male and female patients. The total distribution of male and female individuals amongst all 20 examined COVID-19 patients were 50% (10/20) and 50% (10/20), respectively.
respectively. The mean age of male and female patients was 44.7±17 and 41.7±14.5 years, respectively. Total distribution of respiratory distress, cough, abdominal cramps/diarrhea, fever, and odor disorders amongst all examined patients were 85%, 90%, 20%, 70%, and 85%, respectively. However, there were no statistically significant differences between and within population-based data presented in this study (P < 0.05). No deaths and also progressive and autoimmune diseases were found in the study population. Additionally, none of the patients were received any other anti-viral or other therapeutic options.

Diverse researches have focused on the impact of montelukast as a probable candidate for the treatment of COVID-19\textsuperscript{19-20}. Montelukast is initially and typically used for the treatment of asthma, but it has some anti-viral activities, which have been assessed in some surveys but not approved well\textsuperscript{21,22,25}. Bozek et al.\textsuperscript{9} surveyed elderly patients who suffered from asthma who were treated with montelukast. They found that montelukast administration provided benefits and improved asthma control, while other drugs did not lead to a comprehensive healing of asthma. Then, they performed a retrospective observational survey as an extension of the above project with the same patients on morbidity due to COVID-19\textsuperscript{20}. They found a significant reduction in SARS-CoV-2 infection in the group of elderly asthmatic patients treated with montelukast. Nowak, J.K. & Walkowiak, J.\textsuperscript{33} reported that the administration of antiallergic medications such as montelukast and levetiracetam, and their combination could be effective against COVID-19. In keeping with this, the high safety of montelukast administration for the treatment of viral and respiratory diseases has been reported previously\textsuperscript{20,21,22,25}. Bozek et al.\textsuperscript{9} surveyed computational docking to assess the effects of montelukast on COVID-19 protease catalytic site. They showed a possible inhibitory portion of montelukast in binding to the Mpro catalytic site of the COVID-19 virus, which may modulate and inhibit the viral replication.

Discussions

From the first days of the occurrence of COVID-19 disease, diverse kinds of therapeutic options have been presented to patients\textsuperscript{28}. However, none of them weren’t introduced as definitive and affected treatment\textsuperscript{46}. Otherwise, no specific anti-viral option has been established as an effective agent against COVID-19 virus\textsuperscript{26}. Despite the significant anti-viral effects of remdesivir\textsuperscript{50}, teicoplanin\textsuperscript{39}, nelfinavir\textsuperscript{53}, colistin, valrubicin, icatibant, pofungin acetate, and atazanavir\textsuperscript{15}, carfilzomib, eravacycline, valrubicin, elbasvir, and streptomycin\textsuperscript{48}, thymopentin, carfilzomib, and saquinavir\textsuperscript{41}, indinavir, cobicistat, caspofungin acetate, and atazanavir\textsuperscript{15}, carfilzomib, eravacycline, valrubicin, elbasvir, and streptomycin\textsuperscript{41}, thymopentin, carfilzomib, and saquinavir\textsuperscript{41}, ledipasvir and velpatasvir\textsuperscript{45}, atazanavir, efavirenz, ritonavir, and dolutegravir\textsuperscript{4}, mycophenolic acid, gra-zoprevir, telaprevir, and boceprevir\textsuperscript{21,29}, fomterol and chloriquo-nne\textsuperscript{2}, eriodictyol, isoniazid pyruvate, nitrofurantoin, cepharanthine, ergoloid, and hypericin\textsuperscript{21}, ikarugamycin and molsidomine\textsuperscript{22}, baricitinib\textsuperscript{21}, and lithium\textsuperscript{21} drugs, none of them weren’t introduced as the definitive treatment of COVID-19 disease. Thus, it is essential to work on other therapeutic candidates for the treatment of lethal COVID-19 disease.

The present study disclosed that the oral administration of montelukast tablets (10 mg) for about 10 days could decrease the risk of death in COVID-19 patients. Additionally, findings revealed that all of the clinical signs of COVID-19 patients were gradually disappeared after treatment. Thus, this is the report of the potential of treatment of COVID-19 patients by the oral administration of montelukast tablets (10 mg) for about 10 days.

\[
\text{Patients' odor appeared one to two days after the end of the study experiment. There were no detectable side effects after 10 days of oral administration of montelukast tablets in examined patients.}
\]

\[
\text{Montelukast administration caused a significant decrease in the frequency and severity of wheezing in patients with an upper respiratory tract infection caused by coronavirus, adenovirus, metapneumovirus, and influenza.}
\]

\[
\text{The cough that can progress by ACE inhibition is caused by increased bradykinin and its bronchoconstrictor result, and montelukast, an antagonist of leukotriene D4 (LTD4), has a repressive effect on hypersensitivity of the airway induced by bradykinin\textsuperscript{8,13}. Respiratory failures and acute respiratory distress syndrome (ARDS) are the most causes of death in the COVID-19 patients\textsuperscript{16,19}. ARDS is mainly caused severe lung injuries with a high inflammatory response with an increase in the levels of interleukin-6 (IL-6), IL-8, and IL-1 and tumor necrosis factor (TNF) in an initial phase and other pro-inflammatory cytokines in the later phase of the disease\textsuperscript{21}. These procedures increased leukocyte migration to the affected region, which causes leukocytes accumulation, reactive oxygen secretion, and protease production with severe damages to capillary endothelium and alveolar epithelium\textsuperscript{21,22}. Surveys revealed that the application of montelukast caused a significant reduction in the levels of TNF-\alpha, IL-6, and IL-1\textsuperscript{22}. Additionally, the inhibitory effect of montelukast toward tracheal contraction induced by bradykinin has also been established\textsuperscript{22,23}.}
\]

\[
\text{Furthermore, it has been established that the montelukast decreases the levels of oxidative stress in cells\textsuperscript{23}. Investigations described that high doses and intravenous (IV) administration of montelukast caused a significant decrease in the expression of IL-4, IL-5, IL-13 proteins in the lungs, and anti-inflammatory activities by the T-helper type-2 cytokines suppression\textsuperscript{15,16}. Moreover, montelukast administration caused significant decrease in the frequency and severity of wheezing in patients with an upper respiratory tract infection caused by coronavirus, adenovirus, metapneumovirus, and influenza.}
\]
Thus, montelukast has an effect on events developing with ACE receptors, and also has an anti-inflammatory effect with bradykinin and leukotriene antagonism. Because of COVID-19 has entry into the cell through ACE receptors and caused mortality due to excessive inflammatory processes, it was thought that montelukast may have a limiting effect on the progression of the disease on COVID-19 infection. Anti-COVID-19 activities of montelukast were confirmed in the present survey.

According to our hypothesis, montelukast caused healing effects and prevented from cough, respiratory distress, congestion, and suffocation of patients suffered from COVID-19 and provided more time for the immune system to fight the virus. The author of the present study guesses that the COVID-19 virus causes immunodeficiency reactions by disrupting the complement system, and lung damage is not the direct function of the virus\(^\text{20}\). Thus, patients faced with immunodeficiency reactions caused severe damages to lung and consequent death. Proof of this hypothesis offers practical approaches to develop new drug therapies against COVID-19 disease. Otherwise, the COVID-19 virus is probably caused severe disorders in the immune system of patients and caused subsequent disturbances in the complement and cytokines systems, which resulted in the appearance of clinical signs and death in patients. This is the possible reason for the lack of anti-viral options used for the treatment of disease. However, the establishment of this hypothesis needs further researches.

Our observations are limited by the small group of patients and lack of some other supplementary tests, which may be partly due to avoid wasting time in the publication of the valuable results of this research to scientists around the world and saving millions of lives. Additionally, this is a preliminary work due to the size of the sample, the high dispersion in the age group, and the absence of a control group. However, the author potentially recommended oral administration of montelukast (10 mg) as a potential therapeutic option for the treatment of COVID-19 disease all-around the world.

Conclusions

According to the results of the present survey and also those of other review articles, montelukast is the potential treatment for COVID-19 disease. Our finding revealed that all of the COVID-19 patients were treated after 10 days of oral administration of montelukast tablets (10 mg) for about 10 days. Thus, the general oral administration of montelukast tablets (10 mg) is potentially suggested as a potential treatment for COVID-19 disease—this a preliminary study on the effect of montelukast as a potential treatment for COVID-19 infections. Thus, several double-blind and multifactorial clinical trials should perform to determine the other clinical aspects of the treatment of COVID-19 disease by oral administration of montelukast.

Acknowledgments

The author applied all coordination, work, and costs. There was no funding information and also no conflict of interest to the state.

Bibliographic references


